Zobrazeno 1 - 10
of 234
pro vyhledávání: ''
Autor:
Jessika A. Contreras, Christopher Spencer, Todd DeWees, Bruce Haughey, Lauren E. Henke, Re-I Chin, Randal Paniello, Jason Rich, Ryan Jackson, Peter Oppelt, Patrik Pipkorn, Jose Zevallos, Rebecca Chernock, Brian Nussenbaum, Mackenzie Daly, Hiram Gay, Douglas Adkins, Wade Thorstad
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(28)
PURPOSE The volume treated with postoperative radiation therapy (PORT) is a mediator of toxicity, and reduced volumes result in improved quality of life (QOL). In this phase II trial, treatment volumes were reduced by omitting PORT to the pathologica
Autor:
Michael Penniment, Adam Stoneley, Chris Milross, Danny Rischin, Michael Poulsen, Marnie Collins, Gerald B Fogarty, Michael Collins, Madeleine King, Michael Veness Veness, Benedict Panizza, Andrew Macann, Lizbeth Kenny, June Corry, Mathias Bressel, Sandro V. Porceddu, Howard Liu, Stephen Cooper, Chris Wratten
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(13)
Purpose To report the results of the Trans Tasman Radiation Oncology Group randomized phase III trial designed to determine whether the addition of concurrent chemotherapy to postoperative radiotherapy (CRT) improved locoregional control in patients
Autor:
Bijoyesh Mookerjee, Eduard Gasal, Adil Daud, Keith T. Flaherty, Lynn M. Schuchter, Richard F. Kefford, Zeynep Eroglu, Rene Gonzalez, Jonathan Cebon, Mario Sznol, William H. Sharfman, Sapna Pradyuman Patel, Jeffrey R. Infante, Jeffrey S. Weber, Suman Redhu, Douglas B. Johnson, Robert R. McWilliams, Georgina V. Long, Omid Hamid
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(7)
Purpose To report 5-year landmark analysis efficacy and safety outcomes in patients with BRAF V600–mutant metastatic melanoma (MM) who received BRAF inhibitor dabrafenib (D) and MEK inhibitor trametinib (T) combination therapy versus D monotherapy
Autor:
Naomi B. Haas, Robert J. Motzer, Jae-Lyun Lee, Sergei Varlamov, Arnulf Stenzl, Toni K. Choueiri, Maurizio Voi, Bohuslav Melichar, Marine Gross-Goupil, Milada Zemanova, Weichao Bao, Christian Doehn, Ray McDermott, Evgeny Kopyltsov, Agnieszka Michael, Cora N. Sternberg, Paola Aimone, Lori Wood, Marlene Carrasco-Alfonso, Simon Chowdhury, F. Donskov, Brian I. Rini, Paul Russo, Ho Yeong Lim, M. Neil Reaume
Publikováno v:
Motzer, R J, Haas, N B, Donskov, F, Gross-Goupil, M, Varlamov, S, Kopyltsov, E, Lee, J L, Melichar, B, Rini, B I, Choueiri, T K, Zemanova, M, Wood, L A, Reaume, M N, Stenzl, A, Chowdhury, S, Lim, H Y, McDermott, R, Michael, A, Bao, W, Carrasco-Alfonso, M J, Aimone, P, Voi, M, Doehn, C, Russo, P, Sternberg, C N & PROTECT investigators 2017, ' Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma ', Journal of Clinical Oncology, vol. 35, no. 35, pp. 3916-3923 . https://doi.org/10.1200/JCO.2017.73.5324
Purpose This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. Patients and Methods A total of 1,538 patients with re
Autor:
Allyson J. Ocean, Aditya Bardia, Gregory A. Masters, Pius Maliakal, David M. Goldenberg, Serengulam V. Govindan, Ronald J. Scheff, W. Thomas Purcell, Rebecca S. Heist, D. Ross Camidge, Jordan Berlin, Wells A. Messersmith, Boyd Mudenda, Alexander Starodub, Leora Horn, William A. Wegener, Robert M. Sharkey, Michael J. Guarino
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(24)
Purpose Trop-2, expressed in most solid cancers, may be a target for antibody-drug conjugates (ADCs) in non–small-cell lung cancer (NSCLC). We studied sacituzumab govitecan (IMMU-132), a Trop-2 ADC, for the targeting of SN-38. Patients and Methods
Autor:
Jennifer Beach, Allison Martin, Moshe Chaim Ornstein, Jorge A. Garcia, Timothy D. Gilligan, Beth R. Zanick, Brian I. Rini, Petros Grivas, Paul Elson, Kimberly D Allman, Laura S. Wood
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(16)
Purpose Sunitinib is a standard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosing requires balancing toxicity with clinical benefit. The feasibility and clinical outcome with intermittent sunitinib dosing in patients with
Autor:
William D. Figg, Thomas S. Uldrick, Frank Maldarelli, Mark N. Polizzotto, Cody J. Peer, Margaret Bevans, Denise Whitby, Vikram Khetani, Jerome B. Zeldis, Priscila H. Goncalves, Seth M. Steinberg, Vickie Marshall, Kathleen M. Wyvill, Karen Aleman, Robert Yarchoan, Irini Sereti
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(34)
Purpose Kaposi's sarcoma (KS) is a multicentric tumor caused by Kaposi's sarcoma–associated herpesvirus. Unmet needs include therapies that are oral, anthracycline sparing, and deliverable in resource-limited settings. We evaluated pomalidomide, an
Autor:
Hossein Borghaei, Scott A. Laurie, Christopher T. Harbison, Matthew D. Hellmann, Naiyer A. Rizvi, Neal Ready, Laura Qm Chow, Faith E. Nathan, Julie R. Brahmer, Scott J. Antonia, Scott N. Gettinger, Frances A. Shepherd, David E. Gerber, Jonathan W. Goldman, Rosalyn A. Juergens, Yun Shen
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(25)
Purpose Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non–small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for adva
Autor:
Antonio Pezzutto, Agnieszka Korfel, Martin Dreyling, P. Kiewe, Ulrich Herrlinger, Christian Schmidt, Luisa von Baumgarten, Peter Martus, Uwe Schlegel, Eckhard Thiel, Sied Kebir, Thomas Grobosch
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(15)
Purpose In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or refractory primary CNS lymphoma (PCNSL). Patients and Methods Immunocompetent adults with histologically confirmed PCNSL after experiencing high-dose m
Autor:
Seock-Ah Im, Xiaolu Yin, Joon Oh Park, Keun Wook Lee, Jacqui Rowbottom, Kyung Hee Lee, Mark J. O'Connor, Dae Young Zang, Woo Ho Kim, Eun Kee Song, Yeul Hong Kim, Anitra Fielding, Hoo Geun Chun, Darren Hodgson, Jae Yong Cho, Yung-Jue Bang
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(33)
Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator of DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib. We compared the efficacy of ol